BrightGene Bio-Medical updates on share repurchase program

BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. has announced progress on its share repurchase program, which began on September 26, 2025. The company plans to repurchase shares totaling 1,000 to 2,000,000,000 yuan, primarily for employee stock ownership or equity incentive plans. The program is scheduled to run until September 25, 2026.

As of October 31, 2025, BrightGene Bio-Medical Technology had repurchased 55,880 shares through the Shanghai Stock Exchange's trading system. This represents 0.0132% of the company's total share capital of 423,102,473 shares. The total amount spent on these repurchases was 2,993,933.37 yuan, with transaction prices ranging from 52.96 to 54.28 yuan per share.

The company's board of directors approved this share repurchase plan on September 26, 2025. BrightGene Bio-Medical Technology is committed to adhering to relevant regulations and will continue to disclose the program's progress.